UBS Group

UBS Group’s CERo Therapeutics Warrants CEROW Stock Holding History

UBS Group’s Portfolio CEROW Stock Details CEROW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-496	Closed	-$20	–	10515
2022 Q4	$20	Buy	+496	New	+$26	﹤0.01%	10551

Other funds holding CEROW

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

UBS Group's CEROW Position: Q1 2023 in Review

UBS Group sold out of CERo Therapeutics Warrants (CEROW) in Q1 2023, closing a stake of 496 shares — an estimated $20 sold.

UBS Group first reported a position in CEROW in Q4 2022 and held it in 1 quarter. The position peaked at $20 in Q4 2022. 46 funds tracked by Wall St. Rank hold CEROW as of Q1 2023.

UBS Group reported no remaining CERo Therapeutics Warrants position as of Q1 2023 after selling out during the quarter.
UBS Group sold 496 CERo Therapeutics Warrants shares in Q1 2023, an estimated $20.
UBS Group first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 1 quarter.
UBS Group's CERo Therapeutics Warrants position peaked at $20 in Q4 2022.
46 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.